Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06378346
Status:
RECRUITING
Last Update Posted:
2024-07-11
First Post:
2024-04-18
Brief Title:
GU-01 Glycyrrhizin in Prostate Cancer
Sponsor:
University of Illinois at Chicago
Organization:
University of Illinois at Chicago
Study Overview
Official Title:
GU-01 Glycyrrhizin in Prostate Cancer a Window-of-Opportunity Trial
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GU-01
Brief Summary:
This is a pilot randomized window-of-opportunity treatment trial in which participants with previously untreated prostate cancer PCa who are candidates for surgery radical prostatectomy
Detailed Description:
This is a pilot randomized window-of-opportunity treatment trial in which participants with previously untreated prostate cancer who are candidates for surgery radical prostatectomy will receive one cycle of therapy consisting of Glycyrrhizin GLY Observation Dose Level 1 75mg daily or Dose Level 2 150mg daily for 6 weeks - 2 weeks prior to surgery
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None